We have located links that may give you full text access.
Vitamin D receptor Taq I polymorphism and the risk of prostate cancer: a meta-analysis.
Oncotarget 2018 January 24
Numerous previous studies reported the association of Vitamin D receptor gene Taq I polymorphism with prostate cancer risk, however these results were controversial. In order to provide a relatively comprehensive description of this relationship, we conducted this meta-analysis by searching PubMed, Embase, and China National Knowledge Infrastructure. Finally, 36 studies with 8,423 cases and 8,887 controls were included. Taq I polymorphism was found to marginally increase the prostate cancer risk in recessive genetic model (tt/Tt vs. TT: Odds Ratio (OR) = 0.89, 95% Confidence Interval (CI) = 0.80-1.00, p = 0.05) and allele genetic model (t vs. T allele: OR = 0.91, 95% CI = 0.84-0.99, p = 0.003) in the overall analysis. Subgroup analyses showed that significant increased risk was found in Asians in homozygote model (tt vs. TT: OR = 0.63, 95% CI = 0.41-0.95, p = 0.029) and allele genetic model (t vs. T: OR = 0.78, 95% CI = 0.67-0.90, p = 0.002), and in the subgroup of population-based controls in all the genetic models. These results suggest that Taq I polymorphism might be a risk factor of prostate cancer risk, especially in Asians. It could be considered as a promising target to predict the prostate cancer risk for clinical practice.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app